{"id":67875,"date":"2026-06-10T14:17:10","date_gmt":"2026-06-10T06:17:10","guid":{"rendered":"https:\/\/flcube.com\/?p=67875"},"modified":"2026-06-10T14:17:11","modified_gmt":"2026-06-10T06:17:11","slug":"antengene-launches-phase-i-attract-study-for-atg-201-bispecific-antibody-in-autoimmune-diseases-following-1-18b-ucb-licensing-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67875","title":{"rendered":"Antengene Launches Phase I ATTRACT Study for ATG-201 Bispecific Antibody in Autoimmune Diseases Following $1.18B UCB Licensing Deal"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Antengene Corporation<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6996:HKG\">HKG: 6996<\/a>) announced it has received regulatory clearance from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> to initiate the <strong>Phase I ATTRACT clinical study<\/strong> evaluating its novel <strong>CD19\/CD3 bispecific antibody (BsAb), ATG-201<\/strong>, for the treatment of <strong>B cell-associated autoimmune diseases<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">ATG-201 is a <strong>T cell engager<\/strong> incorporating proprietary <strong>steric hindrance masking technology<\/strong> designed to selectively eliminate <strong>CD19-expressing B cells<\/strong>. The molecule simultaneously binds to <strong>CD3 on T cells<\/strong> and <strong>CD19 on B cells<\/strong>, creating bispecific connectivity that mobilizes the body&#8217;s immune system for precise intervention in B cell-driven pathologies.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-program\" class=\"wp-block-heading\">Clinical Development Program<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study Component<\/th><th>Design<\/th><th>Primary Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Dose Escalation<\/strong><\/td><td>Open-label, ascending doses<\/td><td>Safety, tolerability, MTD determination<\/td><\/tr><tr><td><strong>Dose Expansion<\/strong><\/td><td>Fixed-dose cohorts<\/td><td>Preliminary efficacy, PK\/PD characterization<\/td><\/tr><tr><td><strong>Study Population<\/strong><\/td><td>B cell-associated autoimmune disease patients<\/td><td>Monotherapy evaluation<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>China and Australia<\/td><td>First-in-human assessment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-partnership-amp-commercial-rights\" class=\"wp-block-heading\">Strategic Partnership &amp; Commercial Rights<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In March 2026, Antengene executed a landmark licensing agreement with <strong>UCB<\/strong>, valued at up to <strong>USD 1.18 billion<\/strong>, which grants UCB:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusive global development rights<\/strong> for ATG-201<\/li>\n\n\n\n<li><strong>Worldwide manufacturing authority<\/strong><\/li>\n\n\n\n<li><strong>Complete commercialization rights<\/strong> across all territories<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Under the agreement terms, <strong>Antengene will conduct the initial Phase I ATTRACT study<\/strong> in China and Australia, after which <strong>all subsequent clinical development activities will transition to UCB<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-technology-platform-amp-competitive-differentiation\" class=\"wp-block-heading\">Technology Platform &amp; Competitive Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Steric Hindrance Masking<\/strong>: Proprietary technology designed to minimize off-target effects and enhance therapeutic index<\/li>\n\n\n\n<li><strong>Dual Targeting<\/strong>: Simultaneous engagement of CD19 (B cell marker) and CD3 (T cell receptor)<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Redirects endogenous T cells to specifically eliminate pathogenic B cell populations<\/li>\n\n\n\n<li><strong>Therapeutic Area<\/strong>: Addresses significant unmet need in autoimmune conditions where B cell dysregulation drives disease pathology<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-pipeline-impact\" class=\"wp-block-heading\">Market Context &amp; Pipeline Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Autoimmune Disease Burden<\/strong>: Affects over 7% of global population with limited targeted therapeutic options<\/li>\n\n\n\n<li><strong>Bispecific Antibody Market<\/strong>: Projected to exceed $15 billion by 2030, driven by oncology and autoimmune applications<\/li>\n\n\n\n<li><strong>Antengene Pipeline Strategy<\/strong>: This partnership validates Antengene&#8217;s innovative platform while providing substantial non-dilutive funding<\/li>\n\n\n\n<li><strong>Financial Impact<\/strong>: Upfront payment and milestone structure provides runway for continued pipeline advancement<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, partnership obligations, and financial expectations. Actual results may differ due to clinical, regulatory, and commercial risks inherent in drug development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antengene Corporation (HKG: 6996) announced it has received regulatory clearance from China&#8217;s National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[136,62,926,28],"class_list":["post-67875","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-antengene","tag-clinical-trial-approval-initiation","tag-hkg-6996","tag-multi-specific-antibodies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Antengene Launches Phase I ATTRACT Study for ATG-201 Bispecific Antibody in Autoimmune Diseases Following $1.18B UCB Licensing Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Antengene Corporation (HKG: 6996) announced it has received regulatory clearance from China&#039;s National Medical Products Administration (NMPA) to initiate the Phase I ATTRACT clinical study evaluating its novel CD19\/CD3 bispecific antibody (BsAb), ATG-201, for the treatment of B cell-associated autoimmune diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67875\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antengene Launches Phase I ATTRACT Study for ATG-201 Bispecific Antibody in Autoimmune Diseases Following $1.18B UCB Licensing Deal\" \/>\n<meta property=\"og:description\" content=\"Antengene Corporation (HKG: 6996) announced it has received regulatory clearance from China&#039;s National Medical Products Administration (NMPA) to initiate the Phase I ATTRACT clinical study evaluating its novel CD19\/CD3 bispecific antibody (BsAb), ATG-201, for the treatment of B cell-associated autoimmune diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67875\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-10T06:17:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-10T06:17:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67875#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67875\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Antengene Launches Phase I ATTRACT Study for ATG-201 Bispecific Antibody in Autoimmune Diseases Following $1.18B UCB Licensing Deal\",\"datePublished\":\"2026-06-10T06:17:10+00:00\",\"dateModified\":\"2026-06-10T06:17:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67875\"},\"wordCount\":378,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Antengene\",\"Clinical trial approval \\\/ initiation\",\"HKG: 6996\",\"Multi-specific antibodies\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67875#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67875\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67875\",\"name\":\"Antengene Launches Phase I ATTRACT Study for ATG-201 Bispecific Antibody in Autoimmune Diseases Following $1.18B UCB Licensing Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-10T06:17:10+00:00\",\"dateModified\":\"2026-06-10T06:17:11+00:00\",\"description\":\"Antengene Corporation (HKG: 6996) announced it has received regulatory clearance from China's National Medical Products Administration (NMPA) to initiate the Phase I ATTRACT clinical study evaluating its novel CD19\\\/CD3 bispecific antibody (BsAb), ATG-201, for the treatment of B cell-associated autoimmune diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67875#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67875\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67875#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antengene Launches Phase I ATTRACT Study for ATG-201 Bispecific Antibody in Autoimmune Diseases Following $1.18B UCB Licensing Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antengene Launches Phase I ATTRACT Study for ATG-201 Bispecific Antibody in Autoimmune Diseases Following $1.18B UCB Licensing Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Antengene Corporation (HKG: 6996) announced it has received regulatory clearance from China's National Medical Products Administration (NMPA) to initiate the Phase I ATTRACT clinical study evaluating its novel CD19\/CD3 bispecific antibody (BsAb), ATG-201, for the treatment of B cell-associated autoimmune diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67875","og_locale":"en_US","og_type":"article","og_title":"Antengene Launches Phase I ATTRACT Study for ATG-201 Bispecific Antibody in Autoimmune Diseases Following $1.18B UCB Licensing Deal","og_description":"Antengene Corporation (HKG: 6996) announced it has received regulatory clearance from China's National Medical Products Administration (NMPA) to initiate the Phase I ATTRACT clinical study evaluating its novel CD19\/CD3 bispecific antibody (BsAb), ATG-201, for the treatment of B cell-associated autoimmune diseases.","og_url":"https:\/\/flcube.com\/?p=67875","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-10T06:17:10+00:00","article_modified_time":"2026-06-10T06:17:11+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67875#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67875"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Antengene Launches Phase I ATTRACT Study for ATG-201 Bispecific Antibody in Autoimmune Diseases Following $1.18B UCB Licensing Deal","datePublished":"2026-06-10T06:17:10+00:00","dateModified":"2026-06-10T06:17:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67875"},"wordCount":378,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Antengene","Clinical trial approval \/ initiation","HKG: 6996","Multi-specific antibodies"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67875#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67875","url":"https:\/\/flcube.com\/?p=67875","name":"Antengene Launches Phase I ATTRACT Study for ATG-201 Bispecific Antibody in Autoimmune Diseases Following $1.18B UCB Licensing Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-10T06:17:10+00:00","dateModified":"2026-06-10T06:17:11+00:00","description":"Antengene Corporation (HKG: 6996) announced it has received regulatory clearance from China's National Medical Products Administration (NMPA) to initiate the Phase I ATTRACT clinical study evaluating its novel CD19\/CD3 bispecific antibody (BsAb), ATG-201, for the treatment of B cell-associated autoimmune diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67875#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67875"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67875#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Antengene Launches Phase I ATTRACT Study for ATG-201 Bispecific Antibody in Autoimmune Diseases Following $1.18B UCB Licensing Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67875"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67875\/revisions"}],"predecessor-version":[{"id":67876,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67875\/revisions\/67876"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}